CA2730665A1 - Dosage form containing a statin - Google Patents

Dosage form containing a statin Download PDF

Info

Publication number
CA2730665A1
CA2730665A1 CA2730665A CA2730665A CA2730665A1 CA 2730665 A1 CA2730665 A1 CA 2730665A1 CA 2730665 A CA2730665 A CA 2730665A CA 2730665 A CA2730665 A CA 2730665A CA 2730665 A1 CA2730665 A1 CA 2730665A1
Authority
CA
Canada
Prior art keywords
dosage form
pharmaceutically acceptable
stable
present
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2730665A
Other languages
French (fr)
Other versions
CA2730665C (en
Inventor
Mathew Philip
Naresh Talwar
Shruti Bhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Priority to CA2730665A priority Critical patent/CA2730665C/en
Publication of CA2730665A1 publication Critical patent/CA2730665A1/en
Application granted granted Critical
Publication of CA2730665C publication Critical patent/CA2730665C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Abstract

The present invention relates to a novel stable pharmaceutical dosage form containing a statin and processes to prepare such dosage forms, wherein the dosage form is substantially free of stabilizing agents, and the statin is combined with the following pharmaceutically acceptable excipients: colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate.

Description

DOSAGE FORM CONTAINING A STATUN

FIELD OF THE INVENTION

The present invention relates to a novel dosage form, a process for the manufacturing the same, as well as the composition of the novel dosage form. More specifically, the present invention relates to a dosage form comprising rosuvastatin calcium as a pharmaceutically acceptable active ingredient.

BACKGROUND OF THE INVENTION

Rosuvastatin calcium, known under the brand name Crestor , is a synthetic lipid-lowering agent for oral administration. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)arnino]
pyrimiditl-3-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt. It has the following structural formula:

F

0H1 OH a i NA- Rosuvastatin calcium belongs to the lass of medications known as "statins", which are known to inhibit the 3-hydroxy-3-methyl-glutaryl-coenzyme A ("HMG-CoA") reductase enzyme. HMG-CoA reductase is involved in regulating cholesterol levels.
Statins axe used along with changes to diet and exercise to help control the amount of cholesterol produced by the body. Rosuvastatin calcium can help a person's body decrease low-density lipoprotein (LDL) cholesterol (i.e. bad cholesterol) and triglyceride levels;
increase high-density lipoprotein (l-iDL) cholesterol (i.e. good cholesterol) levels; and decrease the total cholesterol f HDL-cholesterol ratio (TC ; HDL-C Ratio).
This ratio represents the balance between good and bad cholesterol Rosuvastatin calcium is indicated as an adjunct to diet, at least equivalent to the Adult Treatment Panel III (ATP III TLC diet), for the reduction of elevated total cholesterol, (Total-C), LDL-C, Apolipoprotein B ("ApoB"), the Total-C/HDL-C ratio and triglycerides and for increasing HDL-C; in hyperlipidernic and dyslipidemic conditions, when response to diet and exercise alone has been inadequate including:
primary hypercholesterolemia (Type Ha including heterozygous familial hypercholesterolemia and severe non-familial hypercholesterolemia), combined (mixed) dyslipidemia (Type IIb), homozygous familial hypercholesterolemia where rosuvastatin calcium is used either .alone or as an adjunct to diet and other lipid lowering treatment such as apheresis.

Rosuvastatin calcium is also known to be a synthetic, enantiomerically pure lipid-lowering agent. It is a selective, potent and competitive inhibitor of HMG-CoA
reductase. This enzyme catalyses the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in cholesterol biosynthesis. Studies have also shown that rosuvastatin calcium lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver by increasing the number of hepatic LDL receptors on the cell-surface for enhanced uptake and catabolism of LDL.
Additionally, rosuvastatin calcium inhibits the hepatic synthesis of very low density lipoprotein (VLDL), thereby reducing the total number of VLDL and LDL
particles.

According to Canadian Patent No. 2,429,263 (issued March 17, 2009 to AstraZeneca), rosuvastatin, and pharmaceutically acceptable salts of rosuvastatin, can be used in the treatment of heterozygous familial hypercholesterolemia. According to Canadian Patent Application No. 2,560,167 (filed April 25, 2005 by Alcon, Inc.), statins can also be used for the treatment of ocular hypertension and glaucoma.

The preparation of rosuvastatin is described in several references, including European Patent No. 0,521,471 and United States Patent No. 5,260,440 (both issued in 1993 to Shionogi Seiyaku Kabushiki Kaisha and corresponding to Canadian Patent No_
2,072,945), and by M. Watanabe et al. in Bioorg. Med. Chem. 5, 437 (1997).
Canadian Patent Applications Nos. 2,495,296, 2,527,314, 2,543,358, 2,573,857, 2,589,775 and 2,594,017, and international laid open patent applications W02007099561, W02007041666, W02007039287, W02007017117 also describe processes for preparing rosuvastatin_ Canadian Patent Application No, 2,450,820 (filed August 16, 2002 by Teva Pharmaceutical Industries Ltd.) is directed to processes for preparing a calcium salt of a statin from an ester derivative or protected ester derivative of the statin by using calcium hydroxide, Canadian Patent Application No. 2,509,619 (filed December 10, 2002 by Ranbaxy Laboratories Ltd.) is directed to a synthetic route of preparing rosuvastatin.

Canadian Patent Application Nos. 2,495,296 and 2,527,314 (filed August 7, 2003 and June
3, 2004, respectively, by AstraZeneca) relates to a process for manufacture of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) an-ino]pyrimidin 5-yI](3R,5S)-3,5-dihydroxyhept-6-enoie acid calcium salt, which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.

Canadian Patent Application No. 2,537,962 relates to two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(i1 ethylsulfor yl)amino]pyrnxtiid.in 5-yI]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors.

United States Patent No. 7,241,800 (issued July 10, 2007 to Mai De Ltd.) relates to anhydrous amorphous forms of rosuvastatin calcium, fluvastatin sodium and pitavastatin calcium, as well as to processes for their preparation, to pharmaceutical compositions containing them and to methods of treatment using the same.

A problem associated with the chemical compound rosuvastatin is that it readily undergoes degradation under certain conditions such as exposure to atmospheric conditions (i_e_ humidity, oxygen, air and light), thereby significantly reducing the storage life of any pharmaceutical compositions containing rosuvastatin or its salts, such as rosuvastatin calcium. This degradation problem is referred to in Canadian Patent Nos_ 2,313,783 and 2,315,141 (both invented by N.A. Wiggins and JR Creekmore and issued to AstraZeneca). The major degradation products formed are the corresponding (3R,5S) lactone and an oxidation product in which the hydroxyl group adjacent to the carbon-carbon double bond is oxidized to a ketone functionality. Also another problem associated with rosuvastatin is that when it is exposed to light it undergoes photolytic degradation forming two diasteriomeric cyclic products. Such has been referred to in international laid open application W02007/071357 (filed December 18, 2006 by Lek Pharmaceuticals).

To address the issue of degradation in rosuvastatin calcium, pharmaceutical manufacturers have used stabilizing agents. For example, Canadian Patent No.
2,313,783 discloses the use of a tribasic phosphate salt in which the cation is multivalent to provide stability to the composition, thereby avoiding degradation. Canadian Patent No.
2,315,141 discloses the use of an inorganic salt in which the cation is multivalent for stabilizing the rosuvastatin calcium structure.

Canadian Patent Application No. 2,543,716 (filed October 29, 2004 by Athpharma Ltd.) discloses formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statiti, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use.

International laid open application W02007/071357 teaches a formulation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)aminolpyrmudin 5-yl]-(3R,5$)-3,5-dihydroxyhept-6-enoic acid (i.e. rosuvastatin) or a pharmaceutically-acceptable salt thereof for oral use, such as tablets, capsules, powders, granules wherein the rosuvastatin is stabilized by the use of ingredients chosen from two groups.
The first group of ingredients stabilizes rosuvastatin calcium against oxidation and consists of corn starch, silicified microcrystalline cellulose, croscarmellose sodium, and hypromellose. The second group of ingredients inhibit the formation of lactontes consists of corn starch, mannitol, hydroxypropyl cellulose, and hypromellose.
4 Generally, the rosuvastatin calcium formulations of the prior art require the use of stabilizing agents, for example, inorganic salts in which the cation is multivalent, such as tribasic calcium phosphate, and some ingredients which specifically prevent degradation. Usage of stabilizing agents inherently renders the manufacturing process more costly due to the use of additional pharmaceutical excipients, and which, in turn, consumes more time.

There is thus a need for a novel dosage form that overcomes the problems of the prior art, such dosage form containing ,a pharmaceutically acceptable active substance (i.e.
rosuvastatin calcium), which is substantially free of any stabilizing agents used to stabilize the end product from degradation.

SUMMARY OF THE INVENTION

According to an aspect of the present invention there is provided a novel stable pharmaceutical dosage form containing a statin that is substantially free of stabilizing agents, said dosage form comprising a statin combined with the following pharmaceutically acceptable excipients: colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate.

Preferably, the colloidal silicon dioxide is present in an amount ranging from 0.5 to 1.5 %, the microcrystalline cellulose is present in an amount ranging from 25 to 35%, and lactose monohydrate is present in an amount ranging from 50 to 70% by weight of the dosage form.

In a preferred embodiment of the present invention, the statin is rosuvastatin or a pharmaceutically acceptable salt thereof. More preferably, the statin is rosuvastatin calcium-Xn a further aspect of the present invention, there is provided a rosuvastatin dosage form that allows a single daily administration with a prolonged effect, simplified production and is cost effective.

In another aspect of the present invention, there is provided a process for manufacturing the novel dosage form.

The manufacturing process of the present invention is simple and less time consuming.
The dosage forms according to the present invention substantially decrease the formation of lactone or oxidation degradation products in comparison to the commercially available dosage form containing rosuvastatin, hence they present greater stability than what was achieved in the Crestor product Other embodiments and further scope of applicability of the present invention will become apparent from the detailed description and examples given hereinafter.
It should be understood that the detailed description and examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art.

DETAILED DESCRIPTION OF THE INVENTION
Definitions and Nomenclature 'Before the present formulations and methods of use are disclosed and described, it is to be understood by a person skilled in the art that unless otherwise indicated this invention is not limited to specific pharmacologically active agents, specific pharmaceutical carriers, or to particular administration regimens, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the context dearly dictates otherwise. Thus, for example, reference to "an active agent" includes xrUxtures of active agents, reference to "a pharmaceutical carrier" includes combinations of two or more carriers, and the like.

"Optional" or "optionally" means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.

The terms or expressions ""active agent', "active. pharmaceutical ingredient", "drug, "pharmacologically active agent", "pharmaceutically active substance", "pharmaceutically acceptable active agent", "pharmaceutically acceptable active substance" are used interchangeably herein to refer to a chemical material or compound which, when administered to an organism (human or animal, generally human) induces a desired pharmacologic effect. In the context of the present invention, the terms or expressions refer to a compound that is capable of being delivered orally-According to the present invention, the pharmaceutically active substance is a statin, for example, rosuvastatxt. The term "rosuvastatin" as used herein includes all optical isomers, racemic mixtures and the like of the compound and all pharmaceutically acceptable salts, amides, prodrugs and analogs thereof.

Similarly, a "pharmaceutically acceptable salt" or a "pharmaceutically acceptable ester"
of the compound as provided herein is a salt or ester which is not biologically or otherwise undesirable. A pharmaceutically acceptable salt of rosuvastatin is, for example, rosuvastatin calcium.

The terms "effective amount" or "pharmaceutically effective amount" of an active agent, as provided herein, are meant to be a nontoxic but sufficient amount of the active agent to provide the desired therapeutic effect The exact amount required will vary from subject to subject, depending on age, general condition of the subject, the severity of the condition being treated, and the particular active agent administered, and the like. Thus, it is not possible to specify an exact "effective amount"; however, an appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. As' noted below, the typical daily dosage of rosuvastatin calcium is in the range of about d mg to about 100 mg.

The term "excipient' refers to a generally pharmaceutically inactive or inert substance used as a diluent or vehicle for a drug. Different forms of drug administration may require a different excipient and a "pharmaceutically acceptable excipient"
includes a "pharmaceutically acceptable carrier". For example, tablets, troches, pills, capsules, and the like, may contain excipients including binders, such as gum tragacanth, acacia, corn starch or gelatin; a disintegrating agent such as corn starch, potato starch, alginic acid;
and a lubricant such as magnesium stearate. Capsules may contain additional excipients such as a liquid carrier.

By "pharmaceutically acceptable carrier" is meant a carrier comprised of a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected active agent without causing any undesirable biological effects or thteracting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The term "carrier" is used generically herein to refer to any components present in the pharmaceutical formulations other than the active agent or agents, and thus includes diluents, binders, lubricants, disintegrants, fillers, colouring agents, wetting or emulsifying agents, pH buffering agents, preservatives, and the like-The expression "substantially free" is intended to mean that the present invention does not contain any specific amount of stabilizing agent that is sufficient to stabilize the active substance, formulation or end product.

The term "stabilizing agent." refers to any substance or a mixture of substances, which when in contact with- the active agent. in appropriate quantities, will improve the physical and chemical characteristics of the active agent.

According to the present invention, the expression "dosage form` may consist of granules, spheroids, beads, pellets, capsules, tablets or any other suitable unit In the present invention, the dosage form is preferably a tablet-As aforementioned, the present invention relates to a novel stable pharmaceutical dosage form containing a statin, wherein the dosage form is substantially free of stabilizing agents, said dosage form comprising a statin combined with at least the following pharmaceutically acceptable excipients: colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate.

(i} Core Composition (or tablet composition) Generally, a tablet composition is made of several components, such as for example at least one pharmaceutically acceptable active substance (e.g. a statist, rosuvastatin or pharmaceutically acceptable salt thereof) combined with at least one pharmaceutically acceptable excipient. In the present invention, the pharmaceutically acceptable substance is combined with at least three pharmaceutically acceptable excipients, being colloidal silicon dioxide, microcrystallsne cellulose, and lactose monohydrate.

(a) Pharmaceutically acceptable active substance Pharmaceutically acceptable active agents include statins. Suitable statins include, for example, atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. Rosuvastatin and salts thereof are particularly preferred pharmaceutically acceptable active agents, and rosuvastatin calcium is the most preferred.

The pharmaceutically acceptable active agent could be co-administered with another active agent known to a person skilled in the art, such as, for example, simvastatin could be co-administered with ezetinvbe (Vytorin(D), lovastatin with niacin (Advicor ), and atorvastatin with amlodipine (Caduet ).

Each of the active agents in the individual tablets may be in the form of a pharmaceutically acceptable salt, ester, amide, prodrug or other derivative or analog, including active agents modified by appending one or more appropriate functionalities to enhance selected biological properties. Such modifications are known in the art and/or are described in the pertinent texts and literature.

,Pharmaceutical) acceptable excipients As aforementioned the pharmaceutically acceptable active substance of the present invention is combined with three pharmaceutically acceptable excipients, being colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate. The dosage forms of the present invention may include additional pharmaceutically acceptable excipierits, such as diluents, disintegrants, binders, lubricants, glidants, and the like.

Diluents, also termed "fillers", are typically necessary to increase the bulk of a tablet so that a practical size is provided for compression. Suitable diluents include, for example, lactose, spray dried lactose, a-lactose, (3-lactose, Tabletose , various grades of Pharrnatose@, Microtose , Fast Flaw, sorbitol, microcrystalline cellulose, various grades of Avicel , Vivacel , Vivapur , powdered cellulose, kaolin, starch, hydrolyzed starches, pregelatinized starch, alumina, sucrose, dextrins, dextrose, fructose, maltodextrins, and the like.

Disintegrants are used to facilitate tablet disintegration or "breakup" after administration, and are generally starches, days, cellulose and cellulose derivatives, alginic acid or alginates, gums, crospovidone, polarcrtillin potassium, sodium starch glycollate, pregelatinized starchõ and the like, Binders are used to impart cohesive qualities to a tablet formulation, and thus ensure that a tablet remains intact after compression. Suitable binder materials include, but are not limited, to starch (including corn starch and pregelatinized starch), gelatin, sugars (including sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums (e.g., acacia, tragacanth, sodium alginate, celluloses, and Veegum), and synthetic polymers such as polymethacrylates and polyvinylpyrrolidone (povidone), ethylcellulose, hydroxyethyl cellulose, hydroxypropylniethykellulose (HPMC), methylcellulose, polyethylene oxide, and the like.

Lubricants are used to facilitate tablet manufacture. Examples of suitable lubricants include magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, and polyethylene glycol, talc, stearic acid (chemically designated as octadecanoic acid, Ci8H3602), zinc stearate, sodium stearyl fumerate, calcium stearate, and light mineral oil.
The lubricants are preferably present at no more than approximately 0.5 to 2.5 wt. %
relative to tablet weight.

Suitable glidants include colloidal silicon dioxide, silicon dioxide (SiO2) (Aerosil ), magnesium silicate, starch, talc, magnesium trisilicate, etc. Colloidal silicon dioxides are also known to function as an absorbent, anti-caking agent, emulsion stabilizer; glidarit;
suspending agent; and tablet disintegrant.

If desired, the dosage forms may also contain minor amounts of nontoxic auxiliary substances such as antioxidants, for example, ascorbic acid, ascorbyl palmitate, butylated hydroxyl anisole, butylated hydroxyl toulene, potassium meta bisul[ite, propyl gallate, sodium thiosulfate, tocopherol, tocopherol acetate, tocopherol hemisuccinate, TPGS or other tocopherol derivatives, hypophosphorous acid, fumaric acid, monothioglycerol; coloring agents, flavouring agents, surface active agents, such as for example, sodium lauryl sulfate, poly oxyethylene sorbitan fatty acid esters (Tween series), Myrj series, Solutol HS, poly oxyethylene alkyl ethers (Byrj series), poly oxyethylene, castor oil derivatives, polyoxyethylene stearates, sorbitan esters (i.e.
sorbitan fatty acid esters), poloxamers, sucrose fatty acid ester, vitamin E
TPGS, polyethylene glycol fatty acid esters, wetting or emulsifying agents, buffering agents, including for example, citric acid, sodium citrate, dilute HC1, sodium hydroxide, fumaric acid, tartaric acid, malic acid, succinic acid, preservatives, such as methyl and propyl parabens, BKC, thiomersal, and the like. Examples of each the aforementioned agents can also be found in the Handbook of Pharmaceutical Excipients (5th edition) by Raymond C. Rowe, Paul J. Sheskey and Sian C. Owen.

(ii) Coating Composition The coating composition of the present invention can be made of several components.
For example, the coating composition can include a coating agent, alone or in combination with any other pharmaceutically acceptable excipient such as a film forming polymer, anti-tacking agents, glidants, diluents, lubricants, plasticizers, additives, surface active agents, and solvents.

For example, the coating composition of an embodiment of the present invention can comprise a coating agent, such as Opadry IlD, manufactured by Colorcon.

(iii) Additional Coats The end product can further be coated with a non-functional or top coat so as to improve the appearance of the dosage form, such as a tablet In this connection, conventional coating procedures and equipment may be used to coat the dosage units (the drug-contauung tablets, beads or particles).

For detailed information concerning materials, equipment and processes for preparing tablets, beads, drug particles, and delayed release dosage forms, reference may be had to Pharmaceutical Dosage Forms: Tablets, eds. Lieberman sf at. (New York: Marcel Dekker, Inc., 1989), and to Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (Media, PA: Williantis & Willcins,1995).

The novel drug dosage forms of the present invention are to be administered orally to a mammal and can be used to administer rosuvastatin calcium to treat or prevent a variety of disorders,. conditions and diseases. In accordance with the present invention, administration of rosuvastatin calcium may be carried out in order to treat any disorder, condition or disease for which rosuvastatin calcium is generally indicated.
Such disorders, conditions and diseases include those described in the background of the present invention., For administration of rosuvastatin calcium, the typical daily dose is in the range of approximately 5 mg to 100 mg, preferably 5 mg to 60 mg, and more preferably 40 mg.
The exact dosage regimen will depend on a number of factors, including age, the general condition of the patient, the particular condition or disorder being treated, the severity of the patient's condition or disorder, and the like. A standard dose of 10 mg for oral administration, once daily, is recommended in most patients.

EXAMPLES
All of the percentages given hereinabove and below are percentages by weight.
Examples of various formulations of rosuvastatin calcium capsules and/or tablets are provided below.

Table 1 Comparative Formula of the dosage form according to preferred embodiments of the present invention vs. Crestor (AstraZeneca) Rosuvastatin % w/w Function Crestox Function tablets of present invention Rosuvastatin as 5.0%- Active Rosuvastatin as Active Rosuvastatin calcium 14% Rosuvastatin calcium Colloidal Silicon 0.5-1.5% Glidant -Dioxide AerosilS
- Tribasic calcium Stabilizer phosphate Lactose MQnvhydrate 50-70% Diluent Lactose Diluent Monoh drate Microcrystalline 25-35% Diluent Microcrystalline Diluent cellulose Avicel cellulose Cros ovidone 3-5.0% Disintegrant Ciro ovidone Disinte t Magnesium stearate 0,5-1.0% Lubricant Ma esium stearate Lubricant Opadry II Pink Coating agent Ferric oxide Red Colorant Opadry 11 Yellow - Coating agent Ferric oxide Yellow Colorant Hydroxypropyl Film former methyl cellulose Gl ce l triacetate Plasticizer - Titanium Dioxide Opacifier Example #1 Table 2 Lot Size - 974 Tablets Rosuvastatin 5 mg w/w Qty for the lot (g) 1 Rosuvastatin calcium 5.21 5.329 2 Colloidal Silicon Dioxide AerosilD 0.5 0.487 3 Microcrystalline cellulose Avicel(V 34,0 33.116 4 Lactose Monoh drate 5454 52_5S
Crospovidone 5.0 4.870 6 Magnesium stearate 0.75 0.731 7 Opadry II Yellow 3.0% of the tablet weight Manufacturing Process:
Step I - rosuvastatin calcium and portion of lactose monohydrate (10.0 g) are blended together and screened through 420 pm mesh (blend #I.).
Step 2 Aerosil, microcrystalline cellulose (Avicel ) and crospovidone are screened through 420 m and blended with blend #1 for 1 minute to form blend #2.
Step 3 - the remaining portion of lactose monohydrate is screened through 600 m r nesh and blended with blend #2 for 1 to 2 minutes to form blend #3.
Step 4 - magnesium stearate is screened through 420 pm mesh (425 gm) and is then blended with blend # 3 for several minutes (Le. 1-2 minutes) to form the final blend.
Step 5 - the final blend is compressed using a rotary press, so as to form, for example, tablets. The resulting tablets are then coated with, for example Opadry 111 (from Colorcon) to a weight gain of 2% to 3.0% w/w.

The coating process can be performed with conventional coating equipment, for example O'HARA Lab CoatTM.

Example #2 Table 3 Lot Size - 123 Tablets Rasuvastatin 40 mg % W/w Qty for the lot (g) 1 Rosuvastatin calcium 9.80 5.41 2 Colloidal Silicon Dioxide Aerosil 0.5 0261 3 Microc stallirLe cellulose Avicel 34.0 17.8 4 Lactose Monoh drate 50.0 25.82 Cros ovidone 5.0 2.61 6 Magnesium stearate 0.75 0.392 7 Opadry 11 Pink 3.0% of the tablet weight Manufacturing Process:
Step 1 - rosuvastatin calcium and portion of lactose monohydrate (10.0 g) are blended together and screened through 420 m mesh (blend #1).
Step 2 -- Aerosil,, microcrystalline cellulose (Avicel() and crospovidone are screened through 420 m and blended with blend #1 for 1 minute to form blend #2.

Step 3 - the remaining portion of lactose monohydrate is screened through 600 rn mesh and blended with blend #2 for 1 to 2 minutes to form blend #3.
Step 4 - magnesium stearate is screened through 420 gm mesh (425 m) and is then blended with blend # 3 for several minutes (i.e. 1-2 minutes) to form the final blend.
Step 5 - the final blend is compressed using a rotary press, so as to form, for example, tablets. The resulting tablets are then coated with, for example Opadry 113 (from Colorcon) to a weight gain of 2% to 3.0% w/w.

The coating process can be performed with conventional coating equipment, for example O'HARA Lab CoatTM.

Example #3 Table 4 Lot Size - 25000 Tablets Rosuvastatin 20 mg % w/w Qty for the lot (g) 1 Rosuvastatin calcium 6.946 521.0 2 Colloidal Silicon Dioxide Aerosil U.S 37.5 3 Micro stalline cellulose Avicel 101 10.0 750.0 4 Microc stalline cellulose AviceIO 102) 15.0 1125.0 Lactose Monohydrate 63.8 4785.3 6 Cros ovidone 3.0 225.0 7 Magnesium stearate 0.75 563 8 Opadry II Pink 3.0% of the tablet weight Manufacturing Process;
Step 1 - Rosuvastatin calcium and mieroc*ystalline cellulose (Avicel(101) are blended together in a V blender for 3 minutes and screened through 225-250 Itm, mesh (blend #1).
Step 2 - Aerosil, microcrystalline cellulose (Avicel(D102) and crospovidone are blended together in a V-blender for 3 minutes and screened through 1000-1200 m mesh to form blend #2.
Step 3 - lactose monohydrate is screened. through 1000-1200 Rm mesh and blended with blend # 1 and blend #2 for 21 minutes in a Bin Blender to form blend #3.

Step 4 - Magnesium stearate is screened through 420 m mesh and is then blended with blend # 3 for 3 minutes in a Bin Blender to form the final blend.
Step 5 - the final blend is compressed using a rotary press, so as to form, for example, tablets. The resulting tablets are then coated with, for example Opadry II@
(from Colorcon) to a weight gain of 2% to 3.0% w/w.

The coating process can be performed with conventional coating equipment, for example O'HARA Lab Coat=M.

In other words, the process for manufacturing the novel dosage form according to the present invention generally comprises:
- a first step (or steps) of combining a statirt with the following pharmaceutically acceptable excipients: colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate so as to form a blend;
a second step of compressing said blend; and optionally, a third step of applying a coating composition.

Direct compression of powder is a preferred manufacturing technique. However, it is worth mentioning that other dosage forms can be envisaged; though for the purposes of the present invention, the tablet form is preferred.

The dosage form, for example a tablet, of the present invention was subjected to accelerated stability studies as per ICI-I guideline conditions in their primary packaging.
A primary packaging includes tablets packed in high-density polyethylene (HDFE) packs with a desiccant and further induction sealed and also in blister packs.
One (1) month and three (3) months stability studies were conducted and tested for degradation, A comparative study of the stability results for the composition of the present invention versus compositions stabilized with tribasic calcium phosphate (i.e. Crestor) are provided in the following tables.

Table 5 Comparative stability of the dosage form according to a preferred embodiment of the present invention (Rosuvastatin calcium 4:0 mg) vs. Crestor 40mg (AstraZeneca) Composition according to a Creator 40 mg preferred embodiment of the present invention Rosuvastatin calcium 40 mg ExWsed condition 40 C/75% RH 40 C 75% RH
Pack I HDPE Pack* Blister pack TO 2Month 3 Months T=0 1Month 3Month Degradation (Known com ounds Comp 1 0.10% 0.1135 0.10% 0.13 % 0.13% 0.25%6 Comp 2 0.04% 0.04% 0.04% NO ND ND
Cam 3** ND 0.04% 0.10% 0-53% 0.64% 0.85%
Com 4"* 0.06% 0.07% 0.13% 0.03% 0111% 0.22%
Cam 5 ND Ni) ND ND ND ND
Total Known 0.2-00/9 0.2611/0 0.36% 0.69% 0.88% 1.32%
Individual unknown compounds 0.05% 0.05% 0.05% 0.05% 0.05% 0.05%
0.03% 0.03% 0.05% 0.04%
Total unknown 0.08% 0.08% 0.05% 0-104/. 0.09 /a 0.05%
Total Related 0.27% 0.34% 0.41% 0.79% 0.97% 1.37%
= HDPE pack - 50 tablets in 60 cc HDPE bottle with i x 1.0 g Trisorb and induction sealed.
Comp 3 - keto acrid (major degradation product) Comp 4 - lactone (major degradation product) ND - Not Detected T = 0 - time zero analysis Table 6 Comparative Stability of the dosage form according to a preferred embodiment of the present invention (Rostrvastatin 5 mg) vs. Crestor 5mg (AstraZeneca) Composition according to a Crestor 5mg preferred embodiment of the present invention Rosuvastatin 5 m E osed condition 40 C/75% RH 40 C/75% RH
Pack HDPE Pack Blister pack T~ Month 3 Months T=O 1Month 3 Month Degradation Known com ounds Com 1 0.11% 0.12% 0.09% 0.12% 0.12% 0.25%
Conn 2 ND ND ND ND ND ND
Cam 3* 0.04% 0.09% 0.22% 0.75% 0.87% 1.04%
Cam 4* 0.05% 0.06% 0.10% 0.06% 0.26% 0.61%
Comp 5 Total Known 0.20% 0.27% 0.41%
Individual unknown compounds 0.03% 0.03% 0.08% 0.03% 0.04%
0.03% 0.04%0 0.06% 0.03%
0.04%
Total unknown 0.06% 0.03% 0.12% 0.13% 0.07%
Total Related 0.26% 0.30% 0.41% 1.06% 1.38% 1.97%
* HDPE pack - 45 tablets in 150 cc HDPE bottle with 1.0 g Trisorb and induction sealed.
Camp 3 - keto acid (major degradation product) Comp 4 - lactone (major degradation product) ND - Not Detected 1' 0 - time zero analysis Table 7 Comparative stability data of the dosage form according to a preferred embodiment of the present invention (Rosuvastatin calcium 20mg) in different packaging Composition according to a Composition according to a preferred embodiment of the preferred embodiment of the present invention present invention Rosuvastatin calcium 20 mg Rosuvastatin calcium 20 mg Exposed condition 40 C/75% RH 40 C/75 ,6 RH
Pack HDPE Pack* Blister pack-T=O 1Month 3 Months T-0 1Month 3 Nlartrh Degradation (Known compounds) Comp 1 0.09% 0.13% 0.11% 0.09% 0.12% 0.12%
comp 2 <0.06% <0.06% <0.06% <0.06% <0.06% <0.06%
Cam 3*** <0.06% 0.09% 0.16% <O.06% <0.06% 0.06%
Comp 4*** <0.06% 0.06% 0.09% <0.06% 0.08% 0.13%
comp 5 <0.06% <0.06% <0.06% <0.06% <0.06% <0.06%
Individual unknown compounds <0.06% <0.06% <0.06% <0.06% <0.06% <0.06%
Total Related 01090/0 0.28% 036% 0.09% 0.20% 0.31%
HDPE pack -100 tablets in 150 cc HDPE bottle with 1.0 g Trisorb artd induction sealed.
Blister pack - Cold Forming blister with posh-through aluminum fail.
**" Comp $ - keto add (major degradation product) Comp 4 - Iactone (major degradation product) ND - Not Detected T = 0 - time zero analysis Excellent chromatographic resolution between the main peak and its degradation products or impurities was achieved using a C18 reversed column with acidic ammonium acetate and an increasing gradient using acetonitrile and tetrahydrofuran.
Degradation products were quantified at 280 nm. The reporting limit of the degradation products was set at 0.03%.

As can be seen from Tables 5 and 6, the dosage forms according to the present invention substantially avoids the formation of lactone or oxidation degradation products in comparison to the commercially available dosage form containing rsuvastatin calcium, presenting greater stability than what was achieved in the Crestor(V product As can be seen from Table 7, the level of degradation of the active pharmaceutical ingredient in HDPE packs and blister packs is approximately the same, with 0.16% of the oxidation product and 0.09% of the lactone detected in the HDPE packs versus O.06%0 of the oxidation product and 0.13% of the lactone in the blister packs after 3 months storage at 40 C and 75% relative humidity.

From the results provided in Tables 5 to 7, it can clearly be understood that the composition (or formulation) of the present invention is stable without the addition of any stabilizers. The major degradation products, being the lactone and the keto-acid (oxidation product), are well controlled.

Claims (14)

1. A novel stable pharmaceutical dosage form comprising a statin as a pharmaceutically active agent and a pharmaceutically acceptable carrier;

wherein the dosage form is substantially free of stabilizing agents; and the pharmaceutically acceptable carrier comprises the following pharmaceutically acceptable excipients: colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate.
2. The stable dosage form according to claim. 1, wherein the colloidal silicon dioxide is present in an amount ranging from 0.5 to 2.5% by weight of the dosage form, the microcrystalline cellulose is present in an amount ranging from 15 to 55% by weight of the dosage form, and lactose monohydrate is present in an amount ranging from 30 to 70% by weight of the dosage form.
3. The stable dosage form according to claim 1, wherein the colloidal silicon dioxide is present in an amount ranging from 0.5 to 1.5% by weight of the dosage form, the microcrystalline cellulose is present in an amount ranging from 25 to 35% by weight of the dosage form, and lactose monohydrate is present in an amount ranging from 50 to 70% by weight of the dosage form.
4. The stable dosage form according to anyone of claims 1 to 3, wherein the statin is rosuvastatin or a pharmaceutically acceptable salt thereof.
5. The stable dosage form according to claim 4, wherein the pharmaceutically active agent is rosuvastatin calcium.
6. The stable dosage form according to any one of claims 1 to 5, further comprising a lubricant and/or a disintegrant.
7. The stable dosage form according to claim 6, wherein the lubricant is magnesium stearate.
8. The stable dosage form according to claim 6, wherein the disintegrant is crospovidone.
9. The stable dosage form according to any one of claims 1 to 8, wherein the dosage form is in the form of a capsule.
10. The stable dosage form according to any one of claims 1 to 8, wherein the dosage form is in the form of a tablet.
11. A process for manufacturing the stable dosage form according to any one of claims 1 to 10, wherein said process comprises the following steps:

(i) a first step (or steps) of combining a statin with the following pharmaceutically acceptable excipients: colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate so as to form a blend;

(ii) a second step of compressing said blend obtained in step 1; and (iii) optionally, a third step of applying a coating composition.
12. A novel stable pharmaceutical dosage form comprising a core composition and a coating composition;

wherein the core composition comprises a statin and a pharmaceutically acceptable carrier;

wherein the pharmaceutically acceptable carrier comprises the following pharmaceutically acceptable excipients: colloidal silicon dioxide, microcrystalline cellulose, and lactose monohydrate; and the dosage form is substantially free of stabilizing agents.
13. The stable pharmaceutical dosage form according to claim 12, wherein the coating composition comprises a coating agent, alone or in combination with any other pharmaceutically acceptable excipient, including a film forming polymer, anti-tacking agents, glidants, diluents, lubricants, plasticizers, additives, surface active agents, and solvents.
14. The dosage form according to claim 13, wherein the coating agent is combined with a film forming polymer and the film forming polymer is Opadry® or Opadry II®.
CA2730665A 2008-07-15 2009-07-14 Dosage form containing a statin Expired - Fee Related CA2730665C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2730665A CA2730665C (en) 2008-07-15 2009-07-14 Dosage form containing a statin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002637977A CA2637977A1 (en) 2008-07-15 2008-07-15 Dosage form containing a statin
CA2,637,977 2008-07-15
PCT/CA2009/001031 WO2010006451A1 (en) 2008-07-15 2009-07-14 Dosage form containing a statin
CA2730665A CA2730665C (en) 2008-07-15 2009-07-14 Dosage form containing a statin

Publications (2)

Publication Number Publication Date
CA2730665A1 true CA2730665A1 (en) 2010-01-21
CA2730665C CA2730665C (en) 2017-01-03

Family

ID=41549981

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002637977A Abandoned CA2637977A1 (en) 2008-07-15 2008-07-15 Dosage form containing a statin
CA2730665A Expired - Fee Related CA2730665C (en) 2008-07-15 2009-07-14 Dosage form containing a statin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002637977A Abandoned CA2637977A1 (en) 2008-07-15 2008-07-15 Dosage form containing a statin

Country Status (2)

Country Link
CA (2) CA2637977A1 (en)
WO (1) WO2010006451A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200904341A2 (en) * 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Stable pharmaceutical compositions containing rosuvastatin calcium.
ES2589460T3 (en) * 2011-12-08 2016-11-14 Hexal Ag New pharmaceutical composition of statin
CN105796518B (en) * 2016-04-08 2018-06-12 山东省中医药研究院 A kind of diosbulbin B dispersible tablet and preparation method thereof
CN113143882A (en) * 2021-04-30 2021-07-23 海南通用三洋药业有限公司 Preparation method of rosuvastatin calcium capsule and rosuvastatin calcium capsule

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21402A (en) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Lined particles and pharmaceutical forms
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1814541A4 (en) * 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd Stable atorvastatin formulations
EP1923057A1 (en) * 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation

Also Published As

Publication number Publication date
CA2730665C (en) 2017-01-03
CA2637977A1 (en) 2010-01-15
WO2010006451A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
WO2009024889A2 (en) Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2382970B1 (en) Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids
US20070202159A1 (en) Pharmaceutical composition comprising stabilized statin particles
WO2006134604A1 (en) Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
KR20150079454A (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
WO2011019326A2 (en) Solubility and stability enchancing pharmaceutical formulation
EP1968593B1 (en) Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
EP2566465A2 (en) Stable rosuvastatin formulations
CA2730665C (en) Dosage form containing a statin
EP2698159A1 (en) Pitavastatin-containing preparation and method for producing same
CN101972260B (en) Rosuvastatin calcium oral drug composition
EP2233133B1 (en) Stable Rosuvastatin Compositions
WO2010021608A1 (en) Solubility enhancing pharmaceutical formulation
US20150037414A1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
EP1651194B1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
US20100178341A1 (en) BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
US20100144800A1 (en) extended release tablet formulation of niacin
US20120165386A1 (en) Stable oral pharmaceutial composition of atorvastatin
KR101098597B1 (en) Stabilized pharmaceutical compositions of HMG-CoA reductase inhibitor
KR101302306B1 (en) complex for improving, alleviating, treating or preventing of hyperlipidemia
WO2013072770A2 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2009091346A2 (en) Stable pharmaceutical formulation and preparation methods
US20100178338A1 (en) Stabilized pharmaceutical compositions comprising atorvastatin
AU2003254428B2 (en) Stable controlled release pharmaceutical compositions containing Fenofibrate and Pravastatin
WO2010021609A1 (en) Solubility and stability enhancing pharmaceutical formulation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140617

MKLA Lapsed

Effective date: 20200831

MKLA Lapsed

Effective date: 20200831